Monday, October 5, 2026

Elgato Stream Deck Plus Reaches Lowest Price Yet at $159.99 Across Major Retailers

Elgato's Stream Deck Plus is now at its lowest price ever for $159.99, making it an excellent choice for enhancing productivity and streamlining tasks.

LM Salvado

January 21, 2026

Elgato Stream Deck Plus Reaches Lowest Price Yet at $159.99 Across Major Retailers
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

Elgato's Stream Deck Plus is currently available at its lowest price to date, according to The Verge AI. The device is on sale for $159.99 across major retailers including Amazon, Best Buy, and B&H Photo. This discounted price makes it an attractive option for users looking to enhance their productivity and streamline daily tasks.

The Stream Deck Plus offers a range of features designed to simplify workflow automation. It includes eight programmable buttons, four dials, and a small touchscreen. These components work together to allow users to customize their interactions with various applications and devices, from muting video calls to adjusting smart home settings.

According to The Verge AI, the Stream Deck Plus is an upgraded version of Elgato's standard Stream Deck. The Plus model introduces additional functionality with four rotary dials, which provide greater precision in controlling settings like volume or skipping tracks in a music playlist. This enhancement allows for more nuanced interactions compared to the standard model, which relies solely on buttons.

The Stream Deck Plus operates by allowing users to assign specific actions to each button and dial. For example, pressing a button can mute a microphone during a video call, while turning a dial can adjust the volume of a particular application. The touchscreen above the dials displays the current function of each control and enables users to navigate through different profiles or pages of programmed actions.

Elgato has also introduced software updates that enable users to assign up to three standard button or plug-in actions to each dial. This feature significantly increases the versatility of the Stream Deck Plus, making it a more robust tool for task automation.

The real-world impact of the Stream Deck Plus is evident in its ability to reduce the time and effort required to perform repetitive tasks. By automating common actions, users can focus more on their core activities, leading to increased productivity and efficiency. Additionally, the enhanced customization options provided by the dials make it particularly useful for media professionals who need precise control over audio and visual settings.

Looking ahead, potential future developments could include further software enhancements that expand the capabilities of the Stream Deck Plus. Users might also expect to see more integrations with popular applications and services, enhancing the device's utility even further. As technology evolves, the Stream Deck Plus may continue to adapt, offering even more streamlined solutions for task automation.

In this story

LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com